Article Contents ::
- 1 The Brand Name EMENIL Has Generic Salt :: Metoclopramide
- 2 EMENIL Is From Company Astrazeneca Priced :: Rs. 5.13/191.23
- 3 EMENIL have Metoclopramide is comes under Sub class Prokinetics of Main Class Gastrointestinal System
- 4 Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: Prokinetics
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name EMENIL Has Generic Salt :: Metoclopramide
EMENIL Is From Company Astrazeneca Priced :: Rs. 5.13/191.23
EMENIL have Metoclopramide is comes under Sub class Prokinetics of Main Class Gastrointestinal System
Main Medicine Class:: Gastrointestinal System Sub Medicine Class :: Prokinetics
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 10/100|
|EMENIL||Astrazeneca||10 MG||10/100||Rs. 5.13/191.23|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Astrazeneca :: EMENIL||Metoclopramide||Gastrointestinal System||Prokinetics|
Indications for Drugs ::
Gastro-oesophageal reflux disease, Diabetic gastric stasis, Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy, Postoperative nausea and vomiting
Drug Dose ::
Adult: PO Diabetic gastric stasis 10 mg 4 times/day. Usual duration: 2-8 wk. Nausea and vomiting associated w/ cancer chemotherapy or radiotherapy 2 mg/kg 1 hr before start of treatment. Repeat dose 3 times at 2-hrly intervals. May repeat 2 additional doses at 3-hrly intervals if needed. Max: 12 mg/kg/day. Gastro-oesophageal reflux disease 10-15 mg up to 4 times/day, depending on severity of symptoms. Delayed emesis following chemotherapy 20-40 mg 2-4 times/day for 3-4 days. IV Nausea and vomiting associated w/ cancer chemotherapy Highly emetogenic regimens: 2 mg/kg 30 mins before start of treatment. Repeat twice at 2-hrly intervals. Less emetogenic regimens: 1 mg/kg. If vomiting is not well-controlled, 3 additional doses at 2 mg/kg/dose 3-hrly. If vomiting is well-controlled w/ the 1st 3 doses, may reduce dose to 1 mg/kg 3-hrly for 3 additional doses. Intubation of the small intestine; Premed for radiologic examination of the upper GI tract 10 mg as a single direct inj. IV/IM Diabetic gastric stasis 10 mg 4 times/day. Convert to PO when possible. Usual duration: 2-8 wk. IM Post-op nausea and vomiting 10 mg near the end of the procedure. Repeat 4-6 hrly when needed. Renal impairment: Moderate to severe: Reduce dose by at least 50% CrCl (ml/min) <40 Reduce dose by at least 50% Contraindication ::
GI haemorrhage, mechanical obstruction and perforation; phaeochromocytoma; history of seizures.
Drug Precautions ::
Children, elderly. Renal or hepatic impairment, porphyria, epilepsy, Parkinson’s disease, history of depression. Ability to drive or operate machineries may be impaired. Pregnancy and lactation. Monitor patients on prolonged therapy. Increased risk of tardive dyskinesia in patients on prolonged or high-dose treatment.
Drug Side Effects ::
Extrapyramidal symptoms, restlessness, drowsiness, anxiety, diarrhoea, hypotension, hypertension, headache, depression, blood disorders (e.g. aganulocytosis, methaemoglobinaemia), hypersensitivity reactions (e.g. bronchospasm, rash), galactorrhoea or related disorders, transient increase in plasma aldosterone levels. Potentially Fatal: Neuroleptic malignant syndrome; cardiac conduction disorders may occur with IV dosage form.
Pregnancy category ::
Drug Mode of Action ::
Metoclopramide enhances the motility of the upper GI tract and increases gastric emptying without affecting gastric, biliary or pancreatic secretions. It increases duodenal peristalsis which decreases intestinal transit time, and increases lower oesophageal sphincter tone. It is also a potent central dopamine-receptor antagonist and may also have serotonin-receptor (5-HT3) antagonist properties.
Drug Interactions ::
Increased sedative effects with CNS depressants. GI effects antagonised by antimuscarinics and opioids. Reduces absorption of digoxin. Increases absorption of ciclosporin, levodopa, aspirin, paracetamol. Interferes with hypoprolactinaemic effect of bromocriptine. Inhibits serum cholinesterase and prolongs neuromuscular blockade produced by suxamethonium and mivacurium. Potentially Fatal: Serotonin syndrome with sertraline (SSRI).